ORGO (Organogenesis Holdings Inc.) Stock Financials & Earnings

ORGOOrganogenesis Holdings Inc.

Mkt Cap$355M

Revenue (TTM)$564M

Net Income (TTM)$37M

EPS (TTM)$0.11

Free Cash Flow (TTM)-$24M

Gross Margin73.6%

Op. Margin10.0%

Net Margin6.6%

FCF Margin-4.3%

P/S Ratio (TTM)0.6x

P/E Ratio (TTM)9.6x

YoY Rev Growth+17.0%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$108M	$81M	-$4M
Q2 23	$117M	$91M	$10M
Q3 23	$109M	$83M	$8M
Q4 23	$100M	$72M	-$1M
Q1 24	$110M	$81M	-$4M
Q2 24	$130M	$101M	-$14M
Q3 24	$115M	$88M	$6M
Q4 24	$127M	$96M	$10M
Q1 25	$87M	$63M	-$27M
Q2 25	$101M	$73M	-$13M
Q3 25	$151M	$115M	$21M
Q4 25	$226M	$164M	$75M

Revenue Breakdown

Valuation

Operating Cash Flow

Capital Expenditures

CapEx

OpEx vs Revenue Growth (YoY)

Stock-Based Compensation

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$11M	—	—	$74M
Q2 23	$11M	$70M	—	—
Q3 23	$10M	—	—	$64M
Q4 23	$12M	—	—	$61M
Q1 24	$13M	—	—	$72M
Q2 24	$16M	—	—	$77M
Q3 24	$10M	—	—	$72M
Q4 24	$12M	$70M	$4M	—
Q1 25	$11M	—	—	$73M
Q2 25	$10M	—	—	$74M
Q3 25	$13M	—	—	$79M
Q4 25	$10M	—	—	$100M

Revenue Segments

Quarter	Advanced Wound care	Surgical and Sports Medicine	Grant	Product
Q1 23	$101M	$7M	—	—
Q2 23	$110M	$7M	—	—
Q3 23	$101M	$7M	—	—
Q4 23	$93M	$6M	—	—
Q1 24	$104M	$6M	—	—
Q2 24	$123M	$7M	—	—
Q3 24	$108M	$7M	—	—
Q1 25	$80M	$7M	—	—
Q2 25	—	—	$226K	$101M
Q3 25	—	—	$377K	$150M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$89M	$0	$89M
Q2 23	$89M	$0	$89M
Q3 23	$98M	$0	$98M
Q4 23	$104M	$0	$104M
Q1 24	$89M	$0	$89M
Q2 24	$90M	$0	$90M
Q3 24	$94M	$0	$94M
Q4 24	$136M	$0	$136M
Q1 25	$110M	$0	$110M
Q2 25	$73M	$0	$73M
Q3 25	$64M	$0	$64M
Q4 25	$94M	$0	$94M

Shares Outstanding

Revenue Per Employee

Revenue / Employee